All In Biotech

Free tool

FAERS Monitor: Ilevro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203491 or its brand name (Ilevro, Nepafenac). Reports on generic versions are filed under their own applications.

Reports

1,718

Serious

588

34% of reports

Hospitalization

168

Death reported

39

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain376
  • drug ineffective119
  • vision blurred110
  • off label use65
  • eye irritation64
  • product quality issue58
  • visual impairment55
  • liquid product physical issue53
  • cataract52
  • fatigue48
  • chronic kidney disease41
  • incorrect dose administered41
  • cystoid macular oedema35
  • diarrhoea34
  • product container issue31

Reports by year received

View as table
YearReports
200817
20102
20124
201311
201424
201570
2016232
2017577
2018158
2019188
2020143
202180
202243
202354
202456
202539
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,441 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cystoid macular oedemaSignal35231.7166.47,667
liquid product physical issueSignal5389.668.74,524
eye painSignal37682.175.129,932
product container issueSignal3144.431.31,269
eye irritationSignal6413.610.7737
cataractSignal5210.78.2448
vision blurredSignal1109.88.2867
chronic kidney diseaseSignal416.64.9190
visual impairmentSignal555.44.2196
product quality issueSignal585.24.1195
incorrect dose administeredSignal412.21.626
drug ineffective1191.10.91
off label use650.90.71
fatigue480.80.64
diarrhoea340.60.57

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.